Australia is closely awaiting the arrival of retatrutide, a novel dual GIP and GLP-1 receptor agonist that's generating significant buzz in the global weight management landscape. Developed by Novo Nordisk, this https://giantbikehybrid098601.kisa-blog.com/313426/novo-nordisk-s-retatrutide-australia-a-promising-hope-for-weight-management